Please login to the form below

Not currently logged in
Email:
Password:

Dr Robert Kim joins Apellis as chief medical officer

Brings experience from Novartis, Genentech and GSK

Apellis Pharmaceuticals Dr Robert KimDr Robert Kim has taken up a role at Apellis Pharmaceuticals as chief medical officer, bringing to the US clinical stage immunotherapy company experience from Novartis, Genentech and GSK.

While at Genentech he managed the Lucentis phase III clinical programme through to its first approval in wet age related macular degeneration.

Meanwhile, at he served at GSK as VP of clinical ophthalmology, helping build its early stage clinical pipeline, and was VP and head of pharmaceutical product development at Novartis/Alcon.

Most recently he was at retina startup Vision Medicines, where he was chief medical officer and head of R&D.

In his new role at Louisville, Kentucky-based Apellis Dr Kim will help the company optimise its drug development strategy as its clinical programmes progress toward late-stage clinical testing.

Apellis CEO Cedric Francois said: "Bob is an experienced clinical drug developer whose deep knowledge and experience will help us prepare for our confirmatory trials in geography atrophy and the further expansion of our exciting clinical pipeline centred on the inhibition of complement factor C3."

11th August 2016

From: Research

Share

Tags

Subscribe to our email news alerts

Featured jobs

PMHub

Add my company
EPG Health

REACH, ENGAGE & MEASURE HCPs ONLINE - Accomplish meaningful engagement via Medthority (www.medthority.com), a trusted independent medical website. Support the...

Latest intelligence

Value is in the eye of the customer. Co-creation is a bridge to value.
We conducted 16 hours of qualitative interviews with HCPs and Senior Pharma industry leaders in the UK, supported with in-depth industry scanning. Our interviews reveal important insights about the tensions...
Partnering with Patients and Caregivers in Clinical Research
...
Practical advice for Early Scientific Advice (ESA) in HTA submissions
A step-by step guide on the benefits, processes, and key considerations involved in the Healthcare Technology Assessment (HTA) Early Scientific Advice (ESA) consultation as part of planning the holistic evidence...